Article

ASCO: More answers, and questions, on best hormonal therapy for early-stage breast cancer

Author(s):

Debu Tripathy blog image

Debu Tripathy, CURE's editor-in-chief, is in Chicago for the annual meeting of the American Society of Clinical Oncology. He explains an analysis of two early-stage breast cancer studies in premenopausal women. The study revealed that exemestane was better than tamoxifen in patients who had ovarian blockade. After four years there was a reduction in recurrence risk, as well as a slight increase in survival. An analysis that would compare these results to tamoxifen alone is still awaited. "We're not quite ready to change hormonal therapy for all premenopausal women," he says. "But that may end up being the case; we may know more in about six months."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content